Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience

BMC Infectious Diseases
Leonard B JohnsonDavid J Guervil

Abstract

Osteomyelitis is often challenging to treat. This analysis examined the clinical experience of patients with gram-positive osteomyelitis treated with ceftaroline fosamil in the phase 4 Clinical Assessment Program and Teflaro® Utilization Registry (CAPTURE) study. Data including patient demographics, past illnesses, risk factors, disease characteristics, antibiotic use, pathogens isolated, and clinical outcome were collected between September 2013 and February 2015 by review of randomly ordered patient charts from participating sites in the United States. Clinical success was defined as discontinuation of ceftaroline fosamil following clinical cure with no further need for antibiotics or clinical improvement with switch to another antibiotic treatment. A total of 150 patients with gram-positive osteomyelitis were treated with ceftaroline fosamil. Most patients (117/150; 78.0%) were treated with 600 mg ceftaroline fosamil per dose; 143/150 patients (95.3%) received a dose every 12 h. The majority (89/150 patients; 59.3%) had been previously diagnosed with diabetes mellitus or peripheral arterial disease. Osteomyelitis was associated with hardware in 32/150 patients (21.3%). Methicillin-resistant and methicillin-susceptible Staphy...Continue Reading

References

Jul 25, 2000·Postgraduate Medical Journal·J Ciampolini, K G Harding
Apr 2, 2003·The Journal of Antimicrobial Chemotherapy·Alan D TiceDavid A Shoultz
Dec 18, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Benjamin A LipskyUNKNOWN Linezolid Diabetic Foot Infections Study Group
Jul 28, 2004·Lancet·Daniel P Lew, Francis A Waldvogel
Dec 14, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Brad Spellberg, Benjamin A Lipsky
Apr 18, 2013·Journal of Clinical Pharmacy and Therapeutics·R H RimawiP P Cook
Feb 20, 2014·Antimicrobial Agents and Chemotherapy·Anthony M CasapaoMichael J Rybak
Aug 26, 2014·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Felix K Yam, Brian K Kwan
Nov 25, 2014·Diabetes/metabolism Research and Reviews·B A LipskyE J C Goldstein
Apr 22, 2015·Antimicrobial Agents and Chemotherapy·Julie Ann JustoKeith A Rodvold
May 23, 2015·The Journal of Bone and Joint Surgery. American Volume·Hilal Maradit KremersPaul M Huddleston

❮ Previous
Next ❯

Citations

Oct 29, 2019·Expert Opinion on Emerging Drugs·Adamantia LiapikouToni Torres
Aug 28, 2020·SAGE Open Medical Case Reports·Shafee Salloum
Oct 9, 2019·Expert Opinion on Emerging Drugs·Matteo BassettiMark Wilcox

❮ Previous
Next ❯

Methods Mentioned

BETA
amputation

Software Mentioned

CAPTURE

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.